Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis
NCT00213564
·
clinicaltrials.gov ↗
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Rheumatoid Arthritis
Interventions
DRUG:
response to infliximab associated with methotrexate
Sponsor
University Hospital, Rouen